Loading patent…
AssigneeChemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
InventorsWinfried WELS, Congcong ZHANG, Pranav OBEROI, Anne KIEFER
Estimating the term…
The invention pertains to bispecific antibodies having two antigen binding specificities, one binding to an epitope of NKG2-D type II integral membrane protein (NKG2D) and one binding to an antigen associated with a disease, preferably a tumor associated- or tumor specific antigen, such as ErbB2 (HER2), CD19, CD20, GD2, PD-L1, EGFR, or EGFRvIII. The bispecific molecules of the invention are preferably applied in the context of the treatment of tumor diseases or infectious diseases. Surprisingly it was found that the use of NKG2D binding specificities that bind in a competitive manner to the NKG2D receptor with its natural ligands such as MICA reduces or prevents the inhibitory effect of ligand shedding. Another advantage of the present invention lies in a synergistic combination of the bispecific molecules of the invention and chimeric antigen receptor (CAR) based therapy. Further provided are methods for the production of the antibodies of the invention, nucleic acids encoding the bispecific antibodies or fragments thereof, pharmaceutical composition and recombinant cells comprising nucleic acids or antibody proteins.
A method of treating a disease in a subject in need thereof, said method comprising administering to the subject a binding molecule and an immune cell, wherein the binding molecule is at least bispecific and comprises at least a first binding domain and a second binding domain, wherein:
A binding molecule which is at least bispecific comprising at least a first and a second binding domain, wherein
A method of treating a disease in a subject in need thereof, said method comprising administering to the subject an immune cell and a binding molecule, wherein the immune cell expresses an immune cell receptor, wherein the immune cell receptor is NKG2D, or a derivative thereof such as a CAR (NKAR), and wherein the immune cell optionally further expresses an interleukin-15, or an interleukin-15 agonist, and wherein the binding molecule comprises is at least bispecific and comprises at least a first binding domain and a second binding domain, wherein:
Dependencies are inferred from the claim text.